Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
15
0
2

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(17 citation statements)
references
References 1 publication
0
15
0
2
Order By: Relevance
“…Regarding the pharmacokinetics of DDS, this drug can cross both blood-brain and placental barriers and 70% of the drug is plasma protein-bound [ 40 , 41 ]. DDS is extensively metabolized, and its hydroxylated metabolites are found in plasma at concentrations ranging from 0.4–1.2 mg/L 24 hours after the ingestion of 100 mg of the drug [ 6 , 42 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Regarding the pharmacokinetics of DDS, this drug can cross both blood-brain and placental barriers and 70% of the drug is plasma protein-bound [ 40 , 41 ]. DDS is extensively metabolized, and its hydroxylated metabolites are found in plasma at concentrations ranging from 0.4–1.2 mg/L 24 hours after the ingestion of 100 mg of the drug [ 6 , 42 ].…”
Section: Discussionmentioning
confidence: 99%
“…DDS is extensively metabolized, and its hydroxylated metabolites are found in plasma at concentrations ranging from 0.4–1.2 mg/L 24 hours after the ingestion of 100 mg of the drug [ 6 , 42 ]. DDS-NHOH and other hydroxylated metabolites are potent oxidants cause the hematologic adverse effects associated with DDS, including methemoglobinemia and hemolytic anemia [ 6 , 7 , 41 , 43 ]. DDS-NHOH has long been considered to be the responsible for inducing methemoglobin in patients using DDS [ 44 , 45 ] besides accelerating erythrocytic destruction in rats [ 19 , 46 ] and morphological alteration in human erythrocytes [ 19 , 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…The keystone of leprosy therapy is DAP (4,4′-diamino-diphenylsulfone) a sulfone drug, synthetized in 1908 [ 21 , 50 ]. At first, DAP antibacterial activity was not observed [ 50 ], only in 1945 was it adopted in the leprosy treatment as monotherapy. However, resistance estimated at 2–10%, has become a problem [ 6 ].…”
Section: Leprosy Treatment Approachesmentioning
confidence: 99%
“…80%. Pharmacokinetic parameters show a half-life time between 24 to 30 h, and a serum peak concentration within 2 to 8 h [ 50 , 56 ]. Biodistribution assessment reveals DAP presence throughout the organism, including its ability to cross blood–brain and placenta barriers [ 56 ].…”
Section: Leprosy Treatment Approachesmentioning
confidence: 99%
“…7 In detail, dapsone resistance in Ml had been indicated in codons 53 and 55, coding threonine (Thr53), and proline (Pro55). 2,10 Furthermore, dapsone causes nausea, vomiting, and hepatic toxicity, inherently 11,12 ; nevertheless, it is the ensconced drug for leprosy treatment due to structure activity relationship. 2,10 Furthermore, dapsone causes nausea, vomiting, and hepatic toxicity, inherently 11,12 ; nevertheless, it is the ensconced drug for leprosy treatment due to structure activity relationship.…”
Section: Introductionmentioning
confidence: 99%